hepatitis

[VBI Vaccines, Inc.] VBI Vaccines, Inc. announced that the first patient has been dosed in a second Phase IIa/IIb clinical study evaluating VBI-2601, an immunotherapeutic candidate targeting chronic hepatitis B virus.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers showed that the phosphatidylserine (PtdSer) lipid transport proteins, ORP5 and ORP8, which are essential for maintaining plasma membrane (PM) PtdSer levels and hence KRAS PM localization, were required for KRAS oncogenesis.

[European Journal of Immunology] Serum soluble CD137 (sCD137) is associated with inflammatory states, and positively correlated with serum tumor necrosis factor in cirrhotic hepatitis C virus (HCV) patients following virus eradication. Researchers argued against a role of sCD137 in HCV infection and suggested a function of sCD137 in liver cirrhosis.

[American Journal of Gastroenterology] Scientists discuss how hepatitis B virus (HBV) induces inflammation and the extrahepatic manifestations of HBV infection to guide clinical management.

[Aligos Therapeutics, Inc. (Globe Newswire, Inc.)] Aligos Therapeutics, Inc. announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-055009-301 evaluating ALG-055009 for the treatment of nonalcoholic steatohepatitis (NASH).

[Antios Therapeutics, Inc.] Antios Therapeutics, Inc. and Arbutus Biopharma Corporation announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus infection.